systemic lupus erythematosus Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
New/Updated Trials
Online Trials
Languages supported at study center
Age Group

Any (10)

Phase 1 (1)
Phase 1/2 (1)
Phase 2 (1)
Phase 3 (1)
Unknown (6)

Observational (5)
INTERVENTIONAL (1)
Interventional (1)

Acupuncture & Herb Clinic (1)
Assistance Publique - Hôpitaux de Paris (1)
Equillium (1)
Sanofi (1)
University Hospital, Basel, Switzerland (1)
University Hospital, Toulouse (1)
University of Bern (1)
Yale University (1)

No (8)
Yes (2)

Updated trials (1)

No (9)
Yes (1)

All Languages (2)
Arabic (1)
Australian English (1)
English (1)

Adult (18+) (10)
Pediatric (Under 18) (3)

I am/have/had

I am/have/hadlupus

I am/have/hadautoimmune disease

I am/have/hadmyositis

I am/have/hadarthritis

I am/have/hadvasculitis

I am/have/hadantiphospholipid syndrome

I am/have/hadrheumatism

I am/have/hadundifferentiated connective tissue disease

I am/have/hadrheumatic diseases

I am/have/hadscleroderma

I am/have/hadsjogren's syndrome

I am/have/hadsarcoidosis

I am/have/hadskin disease

I am/have/haddermatomyositis

I am/have/hadchest x-ray

I am/have/hadraynaud disease

I am/have/hadbehcet's syndrome

I am/have/hadreactive arthritis

I am/have/hadpolymyalgia

I am/have/hadneuromyelitis optica

added new label for I am/have/had

more

I am looking for

I am looking forimmunosuppressive agents

I am looking forcorticosteroids

I am looking forcyclophosphamide

I am looking forOnline studies

added new label for I am looking for

more

Advanced Filters

Loading...

Found 261 clinical trials

For Seniors
For adults
Recruiting in 10s
Observational Study
all
Dermatology
Recruiting

MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis

To define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse cutaneous or interstitial lung damage of systemic sclerosis.

immunosuppressive agents

raynaud disease

progressive systemic sclerosis

corticosteroids

scleroderma

0 views
16 Feb, 2024
1 location

22
23
24
25
26
27

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.